KARD Kardigan, Inc.

XNAS 12.56 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

KARD $12.56 —
Key stats
$12.56
52-Week Range
$12.23 – $27.00
YTD
-42.91%
IV Rank (30D)
20.8
Straddle Price
$4.95
P/C Vol Ratio
0.27
Market Cap
$1.2B
Open
$12.50
Day Range
$12.25 – $13.07
Volume
832,832
Prev Close
$12.32
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY1.87
Cost of Equity (CAPM)15.42% (VRP-adj)
WACC15.14%
Volatility Risk Premium+104.1pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Book / Price53.4% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$14.67 (Market Anchor value)
SMA 20 / Bollinger Mid$13.99
Bollinger Width / SMA2029.0% (drives anchor stability)
Net Debt$-0.4B
Market Cap$1B
Peers used for multiples: DXCM, EW, GILD, JNJ, LLY, MRK, UNH, VRTX
Blended Fair Value
$43.60
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 41.7× · 7 peers
Peer EV/EBITDA n/a 0% median 28.0× · 8 peers
Peer P/B $52.94 76% median 8.1× · 8 peers
Peer P/S n/a 0% median 6.8× · 8 peers
Market Anchor (SMA50) $14.67 24% stability 5% (BB-width)
Options Expected (B-L 30d) $9.40 0% 9 strikes · skew +0.36
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$1.2B
List Date
2026-06-18
CIK
0002123613
Last Earnings
Nov 12 before open · −9.9% vs ±22.3% expected
Headquarters
South San Francisco, CA
Homepage
https://www.kardigan.bio

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiov…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'26Avg
Jan----
Feb----
Mar----
Apr----
May----
Jun8.41%8.41%
Jul-14.22%-14.22%
Aug0.95%0.95%
Sep-24.74%-24.74%
Oct-0.84%-0.84%
Nov-8.37%*-8.37%
Dec----
Total-35.81%-35.81%
* Only 1 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $14.00
SMA 50: $14.55
SMA 200: —
Current: $13.02
EMA 12: $13.69
EMA 26: $14.09
MACD: -0.3980 | Signal: -0.1400
BEARISH
ADX (14): 16.04
RANGE
+DI: 13.37
−DI: 21.80

Momentum Oscillators

RSI (14): 43.47
NEUTRAL
Stoch %K: 11.13
Stoch %D: 11.70
Williams %R: -82.26

Volume & Volatility

BB Upper: $16.00
BB Lower: $12.00
NEUTRAL
OBV: 454,373
Vol SMA 20: 483,826
Vol ROC: 3.31%
ATR: $1.23
True Range: $0.79
HV 20: 94.6%
HV 30: 88.4%
HV 60: 83.0%

Data Summary

Data Points: 107
Last Updated:
Date Range: 2026-06-18T00:00:00 – 2026-11-18T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Earnings History
1 of 1 under expected move
Avg Expected Move
22.32%
Avg Actual Move
9.95%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2026-11-12 Pre-Market 22.32% 9.95% 0.45x Within

Earnings calendar: this week’s reports with expected vs actual moves →

KARD Options Activity & IV Rank

KARD IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 87.1%
7-DTE IV: —
Expected Move: $4.95
7-DTE Move: $4.90
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 410
Put Volume: 112
P/C Volume: 0.273
BULLISH
Call OI: 676
Put OI: 374
P/C OI: 0.553
Total OI: 1,050

ATM Options Pricing

ATM Call: $2.50
ATM Put: $2.45
Call %: 19.9%
Put %: 19.5%

Chain Summary

Chain Volume: 522
Chain OI: 1,050
Last Updated: 11/19/2026

KARD Implied Volatility

30-day IV
87.1%
Nov 19
IV rank
21Low
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much KARD actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 12th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
12%
vs own history
GEX tilt
-0.67
OI-weighted, today
Vanna tilt
+0.32
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +0.32: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 164.5% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)20.8LowNov 19

Embed KARD IV rank

KARD's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$4.95Nov 19
Beta Analysis

Risk Metrics

Beta: 1.7784
Alpha: -82.81%
Correlation: 0.3310
R-Squared: 11.0%
Stock Volatility: 75.6%
Market Volatility: 14.1%

Analysis Details

Benchmark: SPY
Data Points: 107
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own KARD
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$5.3M
0.00%
#2021 of 3716new13F
Citadel Hedge fund
Ken Griffin
$2.9M
0.00%
#2560 of 6285new13F
Point72 Hedge fund
Steve Cohen
$295K
0.00%
#1724 of 1945new13F
Renaissance Technologies Hedge fund
Jim Simons
$159K
0.00%
#2945 of 3151new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

KARD Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 25,196,212 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

84 filers62,906,534 shares$1.20B value249.67% of float
# Filer Shares Value % of Total % of Float Period
1 HRTG GPE, LLC 16,917,034 $249.53M 20.76% 67.14% 2026-09-30
2 FMR LLC Custodian 8,909,066 $212.48M 17.68% 35.36% 2026-06-30
3 PERCEPTIVE ADVISORS LLC 8,200,662 $195.59M 16.27% 32.55% 2026-06-30
4 T. Rowe Price Investment Management, Inc. 4,207,130 $100.34M 8.35% 16.70% 2026-06-30
5 Capital Research Global Investors 3,617,884 $53.36M 4.44% 14.36% 2026-09-30
6 AllianceBernstein L.P. 1,534,837 $36.61M 3.05% 6.09% 2026-06-30
7 BlackRock, Inc. Custodian 1,905,163 $28.10M 2.34% 7.56% 2026-09-30
8 JPMorgan Chase & Co Custodian 1,759,214 $25.79M 2.15% 6.98% 2026-09-30
9 Jennison Associates LLC 903,575 $21.55M 1.79% 3.59% 2026-06-30
10 Paradigm Biocapital Advisors LP 900,000 $21.46M 1.79% 3.57% 2026-06-30
11 Vanguard Capital Management LLC 1,238,014 $18.26M 1.52% 4.91% 2026-09-30
12 Jupiter Topco LLC 749,703 $17.72M 1.47% 2.98% 2026-06-30
13 Liberty Mutual Group Asset Management Inc. 1,196,411 $17.65M 1.47% 4.75% 2026-09-30
14 T. Rowe Price Associates, Inc. 658,787 $15.71M 1.31% 2.61% 2026-06-30
15 Goldman Sachs Group Inc Custodian 644,969 $15.38M 1.28% 2.56% 2026-06-30
16 Deep Track Capital, LP 600,000 $14.31M 1.19% 2.38% 2026-06-30
17 EVENTIDE ASSET MANAGEMENT, LLC 896,411 $13.22M 1.10% 3.56% 2026-09-30
18 Geode Capital Management, LLC Custodian 756,876 $11.17M 0.93% 3.00% 2026-09-30
19 UBS Group AG Custodian 733,582 $10.82M 0.90% 2.91% 2026-09-30
20 Woodline Partners LP 413,980 $9.87M 0.82% 1.64% 2026-06-30
21 MONTANOVA CAPITAL, LLC 400,000 $9.54M 0.79% 1.59% 2026-06-30
22 Massachusetts Financial Services Co 636,701 $9.39M 0.78% 2.53% 2026-09-30
23 Catalio Capital Management, LP 312,500 $7.45M 0.62% 1.24% 2026-06-30
24 BRAIDWELL LP 300,000 $7.16M 0.60% 1.19% 2026-06-30
25 State Street Corp 455,644 $6.72M 0.56% 1.81% 2026-09-30
1 filers$7.38K notional
# Filer Notional Value % of Total Period
1 Simplex Trading, LLC Custodian $7.38K 100.00% 2026-09-30
# Filer Notional Value % of Total Period

KARD Insider Trading (Form 4)

Latest: 2026-10-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-01 Kristin Marie K Reinke Director Grant (A) +48,368 opt — EDGAR
2026-07-13 PERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director Award (A) +20,706 — EDGAR
2026-06-24 Paul L Berns Director Buy (P) +1,250,000 $16.00 $20.00M EDGAR
2026-06-24 ARCH Venture Partners XIII, LLC Director Buy (P) +1,250,000 $16.00 $20.00M EDGAR
2026-06-24 Kevin Anthony Kelly 10%+ Owner Buy (P) +3,125,000 $16.00 $50.00M EDGAR
2026-06-22 Douglas E. Giordano Director Award (A) +20,706 — EDGAR
2026-06-22 Kimberly J Popovits Director Award (A) +20,706 — EDGAR
2026-06-22 David P Meeker Director Award (A) +20,706 — EDGAR
2026-06-22 Brianne Jahn Chief Financial Officer Award (A) +79,640 — EDGAR
2026-06-22 John B Moriarty Chief Legal Officer Award (A) +47,784 — EDGAR
2026-06-22 Timothy P Walbert Director Award (A) +20,706 — EDGAR
2026-06-22 Jay Edelberg Chief Medical Officer Mixed
Grant +47,784 · Conv +97,587
+145,371 — EDGAR
2026-06-22 Paul L Berns Director Mixed
Grant +20,706 · Conv +13,792,035
+13,812,741 — EDGAR
2026-06-22 Andy Pasternak Chief Strategy Officer Award (A) +79,640 — EDGAR
2026-06-22 Anastasios Gianakakos President & CEO Conv (C) +568,395 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

KARD Insider Holdings

15 insiders · @ $13.02
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Kevin Anthony Kelly 10%+ Owner 16,917,034 $220.26M $50.00M 1 2026-06-24
2 Paul L Berns Director 15,062,741 $196.12M $20.00M 2 2026-06-24
3 ARCH Venture Partners XIII, LLC Director 15,042,035 $195.85M $20.00M 1 2026-06-24
4 ARCH Venture Fund XIII, L.P. 10%+ Owner 13,792,035 $179.57M $0 1 2026-06-22
5 SCHF CIF 2024, L.P. 10%+ Owner 13,792,034 $179.57M $0 1 2026-06-22
6 Anastasios Gianakakos President & CEO 9,806,633 $127.68M $0 1 2026-06-22
7 Jay Edelberg Chief Medical Officer 4,643,167 $60.45M $0 1 2026-06-22
8 Andy Pasternak Chief Strategy Officer 79,640 $1.04M $0 1 2026-06-22
9 Brianne Jahn Chief Financial Officer 79,640 $1.04M $0 1 2026-06-22
10 John B Moriarty Chief Legal Officer 47,784 $622.1K $0 1 2026-06-22
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

KARD Board & Officers

As of SEC filings through Oct 1, 2026

Directors 18

Officers 5

10% owners 13

Changes in the last 10 years (36)
Sep 29, 2026Kristin Marie K Reinke became a director
Jul 13, 2026Perceptive Capital Solutions Holdings LP first on file as a director
Jun 24, 2026Steven Gillis first listed as a director in an SEC filing
Jun 24, 2026Robert Nelsen first listed as a director in an SEC filing
Jun 24, 2026Kristina Burow first listed as a director in an SEC filing
Jun 24, 2026Keith Crandell first listed as a director in an SEC filing
Jun 24, 2026ARCH Venture Partners XIII, L.P. first listed as a director in an SEC filing
Jun 24, 2026ARCH Venture Fund XIII, L.P. first listed as a director in an SEC filing
Jun 22, 2026Hrtg Cif 2024, L.p. first on file as a 10% owner
Jun 17, 2026Timothy P Walbert became a director
Jun 17, 2026Steven Gillis became a 10% owner
Jun 17, 2026Robert Nelsen became a 10% owner
Jun 17, 2026Perceptive Life Sciences Master Fund Ltd became a director
Jun 17, 2026Perceptive Advisors LLC became a director
Jun 17, 2026Paul L Berns became a director
Jun 17, 2026Paul L Berns became a 10% owner
Jun 17, 2026Kristina Burow became a 10% owner
Jun 17, 2026Kimberly J Popovits became a director
Jun 17, 2026Kevin Anthony Kelly became a 10% owner
Jun 17, 2026Keith Crandell became a 10% owner
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-12
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-12 Earnings results EDGAR
2026-11-06 Regulation FD disclosure EDGAR
2026-09-30 Director or officer change · Regulation FD disclosure EDGAR
2026-08-11 Earnings results EDGAR
2026-06-23 Bylaws or fiscal year change EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-12 0001193125-26-456903 EDGAR
2026-08-11 0001193125-26-343418 EDGAR
ETF Holders
18 ETFs hold KARD
18 shown · $31.62M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $10.8M — 2026-10-31
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $9.7M $75.0B 2026-11-17
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $4.3M — 2026-10-31
4 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $2.3M — 2026-10-31
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.02% $2.1M $13.5B 2026-11-17
6 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $1.3M $13.6B 2026-11-17
7 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $280,947 $10.1B 2026-11-17
8 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.02% $266,336 — 2026-10-31
9 RSSL Global X Russell 2000 ETF Global X 0.01% $163,228 — 2026-11-18
10 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $141,653 — 2026-10-31
11 TMED T. Rowe Price Health Care ETF Nport 0.28% $64,276 — 2026-06-30
12 GDOC Goldman Sachs Future Health Care Equity ETF Goldman 0.31% $62,982 $20.2M 2026-11-17
13 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $34,788 — 2026-10-31
14 ITWO ProShares Russell 2000 High Income ETF ProShares 0.01% $19,576 — 2026-11-18
15 URTY ProShares UltraPro Russell2000 ProShares 0.01% $13,724 — 2026-11-18
16 UWM ProShares Ultra Russell2000 ProShares 0.00% $9,068 — 2026-11-18
17 HDG ProShares Hedge Replication ETF ProShares 0.00% $431 — 2026-11-18
18 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.01% $160 — 2026-11-18
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (1 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$0.00$-116.24M$-4.61—
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11

KARD vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.23T 44.0 +45.5% +25.5% 36
JNJ Johnson & Johnson $656.5B 40.5 +7.8% +28.6% 87
MRK Merck & Co., Inc. $339.7B 137.3 +4.9% +25.1% 65
UNH UNITEDHEALTH GROUP INCORPORATED (Delawar $313.5B 21.5 +6.5% −0.8% 100
GILD Gilead Sciences Inc $209.6B — +6.5% +37.8% 63
VRTX Vertex Pharmaceuticals Inc $136.0B 33.8 +10.5% +16.2% 58
EW Edwards Lifesciences Corp $60.5B 58.9 +13.4% +22.1% 18
DXCM DexCom, Inc. $30.8B 31.7 +13.0% +21.1% 39
KARD Kardigan, Inc. Common Stock $1.2B — — −40.8% 16
Peer median $261.6B 40.5 +9.2% +23.6% 60

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
5.69M
SI % of Float
14.81%
Days to Cover
11.19
Short Vol Ratio
74.7%
Free Float
38.46M
Float %
41.1%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-10-01